Study of adults with NF1 and plexiform neurofibromas in Russia
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study is collecting information about adults in Russia with Neurofibromatosis type 1 who have symptomatic plexiform neurofibromas and have not yet been treated with a MEK inhibitor. It aims to better understand the condition and its treatment in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of Neurofibromatosis type 1.
- You must have a plexiform neurofibroma (a tumor along a nerve) that is causing symptoms.
- You cannot have taken a MEK inhibitor for this condition before.
- You cannot have other active cancers needing chemotherapy or radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with neurofibromatosis type 2 (NF2) over time to learn how the condition changes, using repeat MRI scans. The information may help researchers understand disease patterns and improve future treatments.
This study checks whether patient surveys (questionnaires) can reliably measure symptoms and pain in people with NF1 who have plexiform neurofibromas. It helps create better tools for tracking how you feel and how treatments may affect quality of life.
This trial tests an oral medication called PAS-004 for adults with Neurofibromatosis Type 1 who have at least one symptomatic plexiform neurofibroma that cannot be surgically removed. The goal is to see if the drug can shrink these tumors or improve symptoms, and to understand side effects.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Hear when a new Neurofibromatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.